AnaBios
San Diego · 2 known investors
AnaBios provides human primary tissues and cells sourced through a network of hospitals and organ procurement organizations, along with proprietary ex vivo human cardiac and neuronal assay platforms. It serves drug developers and researchers seeking physiologically relevant human data for preclinical drug discovery, safety assessment, and translational research.
Founders & leadership
RF
Richard F. ErdmanDirector
PM
Paul MillerExecutive Officer
JR
Jack ReynoldsExecutive Officer, Director
PC
Peter CrowleyDirector
GG
George GoldsmithDirector
MJ
Martin J. WatersExecutive Officer
AG
Andre GhettiExecutive Officer, Director
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$6.5MraisedJun 2022 · 1 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJun 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Melanie FanDirector
- Andre GhettiExecutive Officer
- Jack ReynoldsExecutive Officer, Director
- Peter CrowleyDirector
- Richard ErdmanDirector
- Paul E MillerExecutive Officer
- David AndersonDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJun 2020 · 16 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJun 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul E MillerExecutive Officer
- George GoldsmithExecutive Officer
- Richard ErdmanDirector
- Peter CrowleyExecutive Officer, Director
- Jack ReynoldsExecutive Officer, Director
- Andre GhettiExecutive Officer
- Martin WatersExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.1M
- Sales commissions
- $490K
- Placement agents
- ARCADIA SECURITIES, LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedJun 2017 · 63 investors · BiotechnologyRule 506(b)
▶$5.8MraisedJun 2017 · 63 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard F. ErdmanDirector
- Paul MillerExecutive Officer
- Jack ReynoldsExecutive Officer, Director
- Peter CrowleyDirector
- George GoldsmithDirector
- Martin J. WatersExecutive Officer
- Andre GhettiExecutive Officer, Director
- Offering amount
- $8.4M
- Amount sold
- $5.8M
- Finders' fees
- $254.1K
- Placement agents
- CIM Securities, LLC, Brookline Group, LLC
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $320.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $200.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.